Protalix BioTherapeutics (PLX) Research & Development (2010 - 2026)
Protalix BioTherapeutics (PLX) posted quarterly Research & Development of $5.4 million for Q1 2026, up 56.14% year-over-year from $3.5 million in Q1 2025, and down 3.71% quarter-over-quarter from $5.6 million in Q4 2025.
Protalix BioTherapeutics (PLX) Research & Development (2010 - 2026) Analysis & Trends
Protalix BioTherapeutics' Research & Development history runs 17 years deep, the most recent figure standing at $5.4 million for Q1 2026.
- In Q1 2026, Research & Development rose 56.14% year-over-year to $5.4 million; the TTM figure through Mar 2026 stood at $21.5 million (up 58.73% YoY), while the FY2025 annual figure was $19.6 million, up 50.88% from the prior year.
- Research & Development for Q1 2026 stood at $5.4 million, down from $5.6 million in the prior quarter.
- The five-year high for Research & Development was $8.8 million in Q1 2022, with the low at $2.9 million in Q1 2024.
- The 5-year median for Research & Development is $4.5 million (2023), against an average of $5.0 million.
- The sharpest annual moves came in 2024 and 2025: Research & Development tumbled 50.62% in 2024, then jumped 102.36% in 2025.
- Protalix BioTherapeutics' Research & Development stood at $5.6 million in 2022, then slumped by 44.77% to $3.1 million in 2023, then jumped by 32.95% to $4.1 million in 2024, then soared by 36.64% to $5.6 million in 2025, then slipped by 3.71% to $5.4 million in 2026.
- Business Quant data shows PLX's Research & Development at $5.4 million in Q1 2026, $5.6 million in Q4 2025, and $4.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 413.13 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 210.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 97.90 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -588.31 Mn |
| 10 | Protalix BioTherapeutics | 190.37 Mn | 149.71 Mn | 12.13 Mn | 4.35 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.35 Mn |
| Mar 31, 2026 | 5.43 Mn |
| Dec 31, 2025 | 5.64 Mn |
| Sep 30, 2025 | 4.47 Mn |
| Jun 30, 2025 | 5.99 Mn |
| Mar 31, 2025 | 3.48 Mn |
| Dec 31, 2024 | 4.12 Mn |
| Sep 30, 2024 | 3.00 Mn |
| Jun 30, 2024 | 2.96 Mn |
| Mar 31, 2024 | 2.89 Mn |
| Dec 31, 2023 | 3.10 Mn |
| Sep 30, 2023 | 3.67 Mn |
| Jun 30, 2023 | 4.48 Mn |
| Mar 31, 2023 | 5.85 Mn |
| Dec 31, 2022 | 5.62 Mn |
| Sep 30, 2022 | 7.39 Mn |
| Jun 30, 2022 | 7.58 Mn |
| Mar 31, 2022 | 8.77 Mn |
| Dec 31, 2021 | 7.64 Mn |
| Sep 30, 2021 | 7.28 Mn |